United Therapeutics Corporation
UTHRHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, United Therapeutics Corporation focuses on Drug Manufacturers - Specialty & Generic services and products. United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United. The $21.36B market capitalization puts UTHR squarely in large-cap range for its industry. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Market Cap
$21.36B
Beta
0.56
P/E (TTM)
17.85
P/E (Fwd)
16.58
EPS (TTM)
$27.89
EPS (Fwd)
$30.03
ROE
19.3%
ROA
11.6%
Cash
$2.66B
Total Debt
$0
Free CF
$557.1M
52W Change
23.0%
Annual Financials
Cash vs Debt
Where UTHR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, UTHR finished 8.13% below its 150-day moving average ($535.59) and 5.97% below its 200-day moving average ($523.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UTHR overbought or oversold?
At the September 3, 2026 close, UTHR's RSI(14) was 45.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
United Therapeutics Corporation reports $2.66B in cash and $0 in total debt. Annual free cash flow of $557.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 19.3%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.6% further supports the picture of efficient asset utilization. Revenue has grown from $1.94B (2022) to $3.18B (2025), reflecting a 64% increase over the period.
The relatively low beta of 0.56 suggests UTHR is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for United Therapeutics Corporation and its sector.